Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

INTESTINAL TOXICITY IN RATS FOLLOWING ADMINISTRATION OF CDK4/6 INHIBITORS IS INDEPENDENT OF PRIMARY PHARMACOLOGY.

Thibault S, Hu W, Hirakawa B, Kalabat D, Franks T, Sung T, Khoh-Reiter S, Lu S, Finkelstein M, Jessen B, Sacaan AI.

Mol Cancer Ther. 2018 Nov 6. pii: molcanther.0734.2018. doi: 10.1158/1535-7163.MCT-18-0734. [Epub ahead of print]

PMID:
30401694
2.

CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats.

Sacaan AI, Thibault S, Hong M, Kondegowda NG, Nichols T, Li R, Rosselot C, Evering W, Fenutria R, Vitsky A, Brown T, Finkelstein M, Garcia-Ocaña A, Khan N, Stewart AF, Vasavada RC.

Mol Cancer Res. 2017 Nov;15(11):1531-1541. doi: 10.1158/1541-7786.MCR-17-0172. Epub 2017 Jul 31.

3.

Mechanistic Investigation of Bone Marrow Suppression Associated with Palbociclib and its Differentiation from Cytotoxic Chemotherapies.

Hu W, Sung T, Jessen BA, Thibault S, Finkelstein MB, Khan NK, Sacaan AI.

Clin Cancer Res. 2016 Apr 15;22(8):2000-8. doi: 10.1158/1078-0432.CCR-15-1421. Epub 2015 Dec 2.

4.

Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist.

Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Cosford ND.

Brain Res. 2008 Oct 9;1234:16-24. doi: 10.1016/j.brainres.2008.07.063. Epub 2008 Jul 28.

PMID:
18692487
5.

Pharmacological characterization of SIB-1663, a conformationally rigid analog of nicotine.

Rao TS, Sacaan AI, Menzaghi FM, Reid RT, Adams PB, Correa LD, Whelan KT, Vernier JM.

Brain Res. 2004 Apr 2;1003(1-2):42-53.

PMID:
15019562
6.
7.

In vivo pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thiophenol hydrochloride (SIB-1553A), a novel cholinergic ligand: microdialysis studies.

Rao TS, Reid RT, Correa LD, Santori EM, Gardner MF, Sacaan AI, Lorrain D, Vernier JM.

Brain Res. 2003 Oct 3;986(1-2):71-81.

PMID:
12965231
8.

In vitro pharmacological characterization of (+/-)-4-[2-(1-methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A), a nicotinic acetylcholine receptor ligand.

Rao TS, Adams PB, Correa LD, Santori EM, Sacaan AI, Reid RT, Suto CM, Vernier JM.

Brain Res. 2003 Aug 15;981(1-2):85-98.

PMID:
12885429
9.

2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

Gasparini F, Lingenhöhl K, Stoehr N, Flor PJ, Heinrich M, Vranesic I, Biollaz M, Allgeier H, Heckendorn R, Urwyler S, Varney MA, Johnson EC, Hess SD, Rao SP, Sacaan AI, Santori EM, Veliçelebi G, Kuhn R.

Neuropharmacology. 1999 Oct;38(10):1493-503.

PMID:
10530811
10.

4-[[2-(1-Methyl-2-pyrrolidinyl)ethyl]thio]phenol hydrochloride (SIB-1553A): a novel cognitive enhancer with selectivity for neuronal nicotinic acetylcholine receptors.

Vernier JM, El-Abdellaoui H, Holsenback H, Cosford ND, Bleicher L, Barker G, Bontempi B, Chavez-Noriega L, Menzaghi F, Rao TS, Reid R, Sacaan AI, Suto C, Washburn M, Lloyd GK, McDonald IA.

J Med Chem. 1999 May 20;42(10):1684-6. No abstract available.

PMID:
10346920
11.

Conformationally restricted analogues of nicotine and anabasine.

Vernier JM, Holsenback H, Cosford ND, Whitten JP, Menzaghi F, Reid R, Rao TS, Sacaan AI, Lloyd GK, Suto CM, Chavez-Noriega LE, Washburn MS, Urrutia A, McDonald IA.

Bioorg Med Chem Lett. 1998 Aug 18;8(16):2173-8.

PMID:
9873508
12.

6-hydroxydopamine lesion of rat nigrostriatal dopaminergic neurons differentially affects nicotinic acetylcholine receptor subunit mRNA expression.

Elliott KJ, Jones JM, Sacaan AI, Lloyd GK, Corey-Naeve J.

J Mol Neurosci. 1998 Jun;10(3):251-60.

PMID:
9770646
13.

The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.

Lloyd GK, Menzaghi F, Bontempi B, Suto C, Siegel R, Akong M, Stauderman K, Velicelebi G, Johnson E, Harpold MM, Rao TS, Sacaan AI, Chavez-Noriega LE, Washburn MS, Vernier JM, Cosford ND, McDonald LA.

Life Sci. 1998;62(17-18):1601-6. Review.

PMID:
9585143
15.

Cloning and stable expression of the mGluR1b subtype of human metabotropic receptors and pharmacological comparison with the mGluR5a subtype.

Lin FF, Varney M, Sacaan AI, Jachec C, Daggett LP, Rao S, Flor P, Kuhn R, Kerner JA, Standaert D, Young AB, Veliçelebi G.

Neuropharmacology. 1997 Jul;36(7):917-31.

PMID:
9257936
16.

Pharmacological characterization of SIB-1765F: a novel cholinergic ion channel agonist.

Sacaan AI, Reid RT, Santori EM, Adams P, Correa LD, Mahaffy LS, Bleicher L, Cosford ND, Stauderman KA, McDonald IA, Rao TS, Lloyd GK.

J Pharmacol Exp Ther. 1997 Jan;280(1):373-83.

17.

(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.

Cosford ND, Bleicher L, Herbaut A, McCallum JS, Vernier JM, Dawson H, Whitten JP, Adams P, Chavez-Noriega L, Correa LD, Crona JH, Mahaffy LS, Menzaghi F, Rao TS, Reid R, Sacaan AI, Santori E, Stauderman KA, Whelan K, Lloyd GK, McDonald IA.

J Med Chem. 1996 Aug 16;39(17):3235-7. No abstract available.

PMID:
8765504
18.

Epibatidine: a nicotinic acetylcholine receptor agonist releases monoaminergic neurotransmitters: in vitro and in vivo evidence in rats.

Sacaan AI, Menzaghi F, Dunlop JL, Correa LD, Whelan KT, Lloyd GK.

J Pharmacol Exp Ther. 1996 Feb;276(2):509-15.

PMID:
8632316
19.
20.

Molecular and functional characterization of recombinant human metabotropic glutamate receptor subtype 5.

Daggett LP, Sacaan AI, Akong M, Rao SP, Hess SD, Liaw C, Urrutia A, Jachec C, Ellis SB, Dreessen J, et al.

Neuropharmacology. 1995 Aug;34(8):871-86.

PMID:
8532169
22.

Profiling of trans-azetidine-2,4-dicarboxylic acid at the human metabotropic glutamate receptors mGlu1b, -2, -4a and -5a.

Knöpfel T, Sakaki J, Flor PJ, Baumann P, Sacaan AI, Veliçelebi G, Kuhn R, Allgeier H.

Eur J Pharmacol. 1995 Feb 15;288(3):389-92.

PMID:
7774685
23.

Metabotropic glutamate receptors and neuronal degenerative disorders.

Schoepp DD, Sacaan AI.

Neurobiol Aging. 1994 Mar-Apr;15(2):261-3. Review. No abstract available.

PMID:
7838307
24.

Pharmacologic regulation of the NMDA receptor-ionophore complex.

Johnson KM, Snell LD, Sacaan AI, Jones SM.

NIDA Res Monogr. 1993;133:13-39. Review. No abstract available.

PMID:
7694149
25.
26.
27.
28.

D,L-(tetrazol-5-yl) glycine: a novel and highly potent NMDA receptor agonist.

Schoepp DD, Smith CL, Lodge D, Millar JD, Leander JD, Sacaan AI, Lunn WH.

Eur J Pharmacol. 1991 Oct 15;203(2):237-43.

PMID:
1686860
29.
30.
33.
34.

Pharmacological profile of NPC 12626, a novel, competitive N-methyl-D-aspartate receptor antagonist.

Ferkany JW, Kyle DJ, Willets J, Rzeszotarski WJ, Guzewska ME, Ellenberger SR, Jones SM, Sacaan AI, Snell LD, Borosky S, et al.

J Pharmacol Exp Ther. 1989 Jul;250(1):100-9.

PMID:
2545856
35.

Equilibrium analysis of [3H]TCP binding: effects of glycine, magnesium and N-methyl-D-aspartate agonists.

Johnson KM, Sacaan AI, Snell LD.

Eur J Pharmacol. 1988 Jul 26;152(1-2):141-6.

PMID:
3061829

Supplemental Content

Loading ...
Support Center